Loading…
Yiling Pharmaceutical Ltd., a Chinese drug manufacturer, received a warning for significant Current Good Manufacturing Practice (CGMP) violations in finished pharmaceutical production. FDA inspectors found that the company's non-dedicated manufacturing equipment was not properly designed or maintained to prevent cross-contamination, including failures to ensure tight seals on ducts and inadequate control of residues from multiple drug products—including therapeutic agents—that were manufactured on the same equipment with degraded seals covered only with tape. The facility's methods, facilities, and controls do not conform to CGMP regulations under 21 CFR parts 210 and 211, rendering the drug products adulterated under the Federal Food, Drug, and Cosmetic Act.